Navigation Links
Going Straight to Chemo May Be Better for Certain Breast Cancers
Date:9/6/2011

TUESDAY, Sept. 6 (HealthDay News) -- Breast cancer patients with the BRCA1 gene mutation have a much better response to neoadjuvant chemotherapy -- chemo given before other treatment -- than other breast cancer patients, a new study finds.

U.S. researchers looked at 317 patients with different stages of breast cancer who underwent neoadjuvant chemotherapy.

Complete pathological response (pCR) -- the disappearance of all evidence of cancer from the breast tissue and lymph nodes -- occurred in 46 percent of those with the BRCA1 mutation, 13 percent of those with the BRCA2 mutation, and 22 percent of patients with neither mutation, the study authors found.

BRCA1 carriers who achieved a pCR after neoadjuvant chemotherapy also had a better five-year, relapse-free survival and overall survival rates, although the latter difference was not statistically significant, said the University of Texas M.D. Anderson Cancer Center researchers.

After neoadjuvant chemotherapy, 61 patients had breast-conserving surgery and 256 underwent mastectomy.

"While hereditary breast cancers typically carry aggressive tumor features compared to sporadic [non-inherited] breast cancers, we found that BRCA1-related tumors were as responsive and sensitive to anthracycline and taxane-based chemotherapy as were sporadic breast cancers," lead author Dr. Banu Arun, a professor in the department of breast medical oncology, said in an M.D. Anderson news release. "These findings may help physicians determine the best treatment method for this subset of women with unique genetic mutations."

The study is published in the Sept. 6 online edition of the Journal of Clinical Oncology.

A lack of prospective studies means there is no consensus on the most effective chemotherapy regimen for breast cancer patients with a BRCA1 mutation, according to Arun.

"This new insight tempts us to speculate that the presence of the BRCA1 mutation determines how some women will respond to neoadjuvant chemotherapy. However, we need future prospective studies with larger cohorts and longer-term follow up to validate these findings and determine optimum treatment," Arun said in the news release.

More information

The U.S. National Cancer Institute explains adjuvant and neoadjuvant therapy for breast cancer.

-- Robert Preidt

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, Sept. 6, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Going Full-Tilt Into Turns May Ease Motion Sickness on Trains
2. Afghan Medical Staff Face Ongoing Security Threats: Study
3. More People May Benefit From Going Gluten-Free
4. Childhood cancer survivors are at increased risk for ongoing post-therapy GI complications
5. Ongoing relationship with care provider key for patients with a chronic condition: UBC study
6. Researchers find many elderly men are undergoing unnecessary PSA screenings
7. Negative attitudes toward fat bodies going global, study finds
8. Going Green May Cut Hospital Costs
9. Many Higher-Income Parents Forgoing Kids Vaccinations: Report
10. Younger Men Not Going to the Doctor Enough, Survey Shows
11. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Going Straight to Chemo May Be  Better for Certain Breast Cancers 
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing ... who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can ... they are free from the shame, stigma, and harmful labeling believed to ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, ... is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... of neurosurgeons in Michigan performing minimally invasive back surgery that often results in ...
(Date:2/22/2017)... ... , ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: ... 1:00 PM ET. A recording of the webinar will also be made available following ... you want to find out what really happened in the seniors housing and care ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Mass. , February 23, 2017 - ...   ... Honoring Rare Disease Day Open to All at http://www.shire.com/RareCount   ... today announced the launch of ,Rare Count, in honor of Rare ... diseases, which equates to nearly one in 20 global citizens. It ...
(Date:2/22/2017)... , Feb. 22, 2017 IRIDEX Corporation (Nasdaq: ... release financial results for the fourth quarter and 2016 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds leading ... Description The Global Spinal Cord Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology: